CN110946857A - Gallocatechin and its application in preparation of intestinal pathogenic bacteria medicine and feed additive - Google Patents
Gallocatechin and its application in preparation of intestinal pathogenic bacteria medicine and feed additive Download PDFInfo
- Publication number
- CN110946857A CN110946857A CN201911279534.1A CN201911279534A CN110946857A CN 110946857 A CN110946857 A CN 110946857A CN 201911279534 A CN201911279534 A CN 201911279534A CN 110946857 A CN110946857 A CN 110946857A
- Authority
- CN
- China
- Prior art keywords
- gallocatechin
- pathogenic bacteria
- preparation
- feed additives
- bacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses gallocatechin and a preparation method thereof for intestinal pathogenic bacteria drugs and feed additives, wherein the intestinal pathogenic bacteria drugs and feed additives are prepared by taking gallocatechin as a raw material, the gallocatechin is used as a derivative prepared by taking gallocatechin as a framework, and the targeted intestinal pathogenic bacteria are enterotoxigenic escherichia coli K88, K99 and 987P. The invention proves that the gallocatechin has good antibacterial effect on intestinal pathogenic bacteria through a plurality of method researches; it is proved to be non-toxic, odorless, non-irritant to organism and non-three-cause effect on cell level. Gallocatechin as a natural extract is widely applied to the aspect of natural food preservatives, which lays a safe foundation for animal use, provides candidate substances for the discovery of novel medicines and antibiotic substitutes for resisting intestinal pathogenic bacteria diseases, and has good application prospect in the aspect of prevention and treatment of the intestinal pathogenic bacteria diseases.
Description
Technical Field
The invention relates to the technical field of veterinary drugs, in particular to gallocatechin and application thereof in preparation of enteric pathogenic bacteria drugs and feed additives.
Background
Colibacillosis of piglets is the most common intestinal infectious disease of newborn piglets, and mainly comprises newborn piglet diarrhea (commonly called yellow and white scour of piglets), weaned piglet diarrhea or edema disease and the like. Piglets can grow from hours to one week after birth, are mostly 1-3 days old, are characterized by severe diarrhea, yellow or yellow-white serous feces discharge and rapid dehydration death, have no vomit phenomenon in most cases, and have extremely high morbidity and mortality; the epidemic has no obvious seasonality; the epidemic range of the disease is wide, and different regions all over the world are reported, which brings serious harm to pig raising production.
Pathogenic escherichia coli is a main pathogenic bacterium of colibacillosis of piglets, and can be divided into 3 types according to virulence characteristics and different disease symptoms caused by the virulence characteristics: enterotoxigenic escherichia coli, shiga toxin-producing escherichia coli, adhesive and exfoliative escherichia coli and the like. Among them, enterotoxigenic escherichia coli causing diarrhea in piglets often has adhesins on the surface (K88, K99, 987P, F41, and the like). The serotypes in different regions are different, and the dominant serotypes in different pig farms or groups in the same region are not completely consistent.
The control measures of colibacillosis of piglets are mainly prevention, are assisted by drug treatment, the most effective measure for preventing the colibacillosis of the piglets is to adopt vaccines to immunize pregnant sows, and the newborn piglets can obtain protective antibodies through colostrums, but due to numerous serology, pathogenic bacteria serotypes in disease sites and vaccine serotypes can not be matched or are not completely covered, and the situation of vaccine immunity failure can exist, a large amount and unreasonable use of antibacterial drugs lead to drug-resistant bacteria and drug residues, the reports of the literatures show that intestinal pathogenic bacteria clinically separated from the world have drug resistance in different degrees, Zhang Dong and the like separate from 10 large-scale pig farms in Yudong, Yuxi, Yunan and North Henan and produce ESBLs gene positive detection rate of 82.39%, which shows that colibacillus resistant colibacillus β -lactam antibiotics widely exist in the large-scale pig farms in Henan province, Zhang and the colibacillus resistant bacteria have strong drug resistance of different areas in 2010, such as Shinylamine resistance of Xingnamin, amoxicillin, ampicillin, penicillin β%, gentamicin, penicillin is 100.7.7% and 8.51.7%, and 27.6% for pigs, and 27.6.7.7%, respectively, and 49% for tetracycline resistant strains of the results of the antibiotic resistance of the antibiotic in the pig origin of the pig.
The existing measures for preventing and treating colibacillosis of piglets mostly adopt vaccines and medicines, easily cause the problems of vaccine immunity failure, bacterial strain resistance, medicine residue and the like, and have serious influence on long-term green development of the breeding industry and food sanitation and safety. Therefore, in order to reduce the economic loss caused by intestinal colibacillosis, reduce bacteria, improve the economic benefit of pig industry, and protect the health of animals and human beings, the development of novel antibiotic substitutes and antibacterial drugs is urgent.
Disclosure of Invention
The invention provides gallocatechin and a method for preparing an intestinal pathogenic bacterium medicament and a feed additive thereof, aiming at overcoming the defects of poor control effect of piglet escherichia coli and mismatching of pathogenic bacterium serotypes and vaccine serotypes in the prior art. The gallocatechin and the application thereof in preparing the intestinal pathogenic bacteria medicament and the feed additive have the characteristics of good antibacterial effect, no toxicity, no peculiar smell, no stimulation to organisms, no three-cause effect and the like.
In order to achieve the purpose, the invention provides the following technical scheme: gallocatechin and preparation of enteric canal pathogenic bacteria medicine and feed additive thereof, wherein the enteric canal pathogenic bacteria medicine and feed additive prepared by taking gallocatechin as raw material are enterotoxigenic escherichia coli K88, K99 and 987P.
Preferably, the minimum inhibitory concentration of the gallocatechin to Escherichia coli K88, K99 and 987P is 256 mug/ml, and the minimum bactericidal concentration is 512 mug/ml.
Preferably, the test is repeated at least 3 times independently, and the results are expressed as mean and standard error using one-way analysis of variance and T-test analysis.
Preferably, the statistical analysis adopts P < 0.05 as a test standard with significant statistical difference, and the analysis software is GraphPad Prism 5.
Preferably, the purified Escherichia coli K88, K99 and 987P colonies are picked respectively by using a sterile inoculating loop, are fully dispersed in a Macconkey liquid culture medium, and are prepared into a 0.5 McLeod turbidimetric standard bacterial suspension by a McLeod turbidimetric method.
Preferably, the gallocatechin solutions with different concentrations after dilution by multiple times of the MacConkey liquid culture medium are respectively added into sterile bacteria bottles, and only the MacConkey liquid culture medium has no gallocatechin solution as a growth control.
Preferably, 0.5 McLeod standard bacterial suspension is equivalently inoculated in the bacterial bottle, the bacterial bottle is placed in a shaking table at 37 ℃ for shake culture, bacterial liquid is taken every two hours, diluted and coated on a Macconk plate for viable count, and the result is expressed by CFU/ml.
Preferably, the enteric pathogenic bacteria drug and the feed additive are derivatives prepared by taking gallocatechin as a framework.
Compared with the prior art, the invention has the beneficial effects that:
according to the invention, the gallocatechin is found to be used for resisting enterotoxigenic escherichia coli for the first time, and the gallocatechin is proved to have a good antibacterial effect on enteropathogenic bacteria through a plurality of method researches; proved to be nontoxic, free from toxic and side effects and peculiar smell at the cellular level, free from stimulation to the organism and free from three causes of action. Gallocatechin as a natural extract is widely applied to the aspect of natural food preservatives, which lays a safe foundation for animal use, provides candidate substances for the discovery of novel medicines and antibiotic substitutes for resisting intestinal pathogenic bacteria diseases, and has good application prospect in the aspect of prevention and treatment of the intestinal pathogenic bacteria diseases.
Drawings
FIG. 1 is a growth curve of E.coli K88;
FIG. 2 is a growth curve of E.coli K99;
FIG. 3 shows the growth curve of E.coli 987P.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Referring to fig. 1-3, the present invention provides a technical solution: a gallocatechin and its use in preparing enteric canal pathogenic bacteria medicine and feed additive, an enteric canal pathogenic bacteria medicine and feed additive prepared from gallocatechin as raw material, the enteric canal pathogenic bacteria medicine and feed additive are derivatives prepared by using gallocatechin as skeleton, the targeted enteric canal pathogenic bacteria are enterotoxigenic Escherichia coli K88, K99 and 987P, the minimum inhibitory concentration of gallocatechin to Escherichia coli K88, K99 and 987P is 256 mug/ml, the minimum bactericidal concentration is 512 mug/ml, all tests are repeated for at least 3 times independently, the result is expressed by mean value and standard error, single-factor variance analysis and T detection analysis are used, all statistical analysis adopt P < 0.05 as test standard with significant statistical difference, the analysis software is GraphPad Prism 5, purified Escherichia coli K88, purified Escherichia coli, K99 and 987P bacterial colonies are fully dispersed in a Macconyk liquid culture medium, a Macconyk turbidimetric method is used for preparing a 0.5 Macconyk turbidimetric standard bacterial suspension, gallocatechin solutions with different concentrations are respectively added into sterile bacteria bottles after the Macconyk liquid culture medium is diluted by times, only the Macconyk liquid culture medium does not contain the gallocatechin solution as a growth control, 0.5 Macconyk turbidimetric standard bacterial suspension is equivalently inoculated into the bacteria bottles, the bacteria bottles are placed in a 37-DEG shaking table for shaking culture, bacterial liquid is taken out by times and diluted and coated on a Macconyk plate every two hours for viable count, and the result is expressed by CFU/ml.
Unless otherwise indicated, reagents and materials used in the following examples were all commercially available. The embodiment of the invention takes the escherichia coli K88, K99 and 987P in intestinal pathogenic bacteria as examples, and other intestinal pathogenic bacteria have inhibiting and killing effects on the substances.
Example 1:
and (3) measuring the minimum inhibitory concentration and the minimum bactericidal concentration of the gallocatechin to escherichia coli K88, K99 and 987P:
as can be seen from Table 1, gallocatechin, at a concentration of 256. mu.g/ml, had an inhibitory effect on the growth of intestinal pathogens, and at a concentration of 512. mu.g/ml, had a bactericidal effect on intestinal pathogens.
Table 1 minimum inhibitory and bactericidal concentrations of gallocatechin against e.coli K88, K99, 987P:
table 1: the gallocatechin has minimum inhibitory concentration and minimum bactericidal concentration to Escherichia coli K88, K99, 987P
Example 2:
the inhibiting effect of gallocatechin on growth curves of escherichia coli K88, K99 and 987P:
respectively picking purified Escherichia coli K88, K99 and 987P colonies by using sterile inoculating loops, fully dispersing in Macconkey liquid culture medium, and preparing 0.5 McLeod turbidimetric standard bacterial suspension by McLeod turbidimetric method.
The gallocatechin solutions with different concentrations after dilution by multiple proportion of the MacConkey liquid culture medium are respectively added into a sterile bacterial bottle, and only the MacConkey liquid culture medium without the gallocatechin solution is used as a growth control.
And (3) equivalently inoculating 0.5 McLeod standard bacterial suspension into the bacterial bottle, placing the bacterial bottle on a 37-DEG shaking table for shake culture, taking bacterial liquid at intervals of two hours, diluting the bacterial liquid in a multiple ratio, coating a Macconk plate, and counting the viable bacteria, wherein the result is expressed by CFU/ml.
As can be seen from the growth curve of Escherichia coli K88 in FIG. 1, when the final concentration of gallocatechin is 256 μ g/ml (i.e. 1MIC value), the difference of bacterial count at each time point within 1-13h is significant compared with the control group (without gallocatechin), which indicates that gallocatechin has antibacterial effect on intestinal pathogenic bacteria when the concentration of gallocatechin is 256 μ g/ml. When the final concentration of gallocatechin was 512. mu.g/ml (i.e., 2 MIC), the enteric bacteria were completely killed by the 2 nd hour of the culture.
As can be seen from the growth curve of Escherichia coli K99 in FIG. 2, when the final concentration of gallocatechin is 256 μ g/ml (i.e. 1MIC value), the difference of bacterial count at each time point within 1-13h is significant compared with the control group (without gallocatechin), which indicates that gallocatechin has antibacterial effect on intestinal pathogenic bacteria when the concentration of gallocatechin is 256 μ g/ml. When the final concentration of gallocatechin was 512. mu.g/ml (i.e., 2 MIC), the enteric bacteria were completely killed by the 2 nd hour of the culture.
As can be seen from the growth curve of Escherichia coli 987P in FIG. 3, when the final concentration of gallocatechin is 256 μ g/ml (i.e. 1MIC value), the difference of bacterial count at each time point within 1-13h is significant compared with the control group (without gallocatechin), which indicates that gallocatechin has antibacterial effect on intestinal pathogenic bacteria when the concentration of gallocatechin is 256 μ g/ml. When the final concentration of gallocatechin was 512. mu.g/ml (i.e., 2 MIC), the enteric bacteria were completely killed by the 2 nd hour of the culture.
The results show that the gallocatechin can not only inhibit the growth of escherichia coli K88, K99 and 987P, but also kill escherichia coli K88, K99 and 987P.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (8)
1. Gallocatechin and application thereof in preparation of enteric pathogenic bacteria medicines and feed additives are characterized in that: the intestinal pathogenic bacteria of the medicine and the feed additive prepared by taking the gallocatechin as the raw material are enterotoxigenic escherichia coli K88, K99 and 987P.
2. The gallocatechin as claimed in claim 1, and its use in preparation of enteric pathogenic bacteria drugs and feed additives, is characterized in that: the minimum inhibitory concentration of the gallocatechin to Escherichia coli K88, K99 and 987P is 256 mug/ml, and the minimum bactericidal concentration is 512 mug/ml.
3. The gallocatechin as claimed in claim 1, and its use in preparation of enteric pathogenic bacteria drugs and feed additives, is characterized in that: the test was repeated at least 3 times independently, with the results expressed as mean and standard error, using one-way anova and T-test analysis.
4. The gallocatechin as claimed in claim 1, and its use in preparation of enteric pathogenic bacteria drugs and feed additives, is characterized in that: the statistical analysis adopts P < 0.05 as the test standard with significant statistical difference, and the analysis software is GraphPad Prism 5.
5. The gallocatechin as claimed in claim 1, and its use in preparation of enteric pathogenic bacteria drugs and feed additives, is characterized in that: and respectively picking purified escherichia coli K88, K99 and 987P bacterial colonies by using an aseptic inoculating loop, fully dispersing the bacterial colonies in a Macconkey liquid culture medium, and preparing a 0.5 McLeod turbidimetric standard bacterial suspension by using a McLeod turbidimetric method.
6. The gallocatechin as claimed in claim 5, and its use in preparation of enteric pathogenic bacteria drugs and feed additives, is characterized in that: and respectively adding the gallocatechin solutions with different concentrations after dilution by a MacConkey liquid culture medium in a sterile bacterial bottle, wherein the growth control only comprises the MacConkey liquid culture medium without the gallocatechin solution.
7. The gallocatechin as claimed in claim 6, and its use in preparation of enteric pathogenic bacteria drugs and feed additives, is characterized in that: and (3) equivalently inoculating 0.5 McLeod standard bacterial suspension into the bacterial bottle, placing the bacterial bottle in a shaking table at 37 ℃ for shake culture, taking bacterial liquid at intervals of two hours, diluting and coating a Mackanka plate in a double proportion, and counting viable bacteria, wherein the result is expressed by CFU/ml.
8. The gallocatechin as claimed in claim 6, and its use in preparation of enteric pathogenic bacteria drugs and feed additives, is characterized in that: the intestinal pathogenic bacteria medicine and the feed additive are derivatives prepared by taking gallocatechin as a framework.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911279534.1A CN110946857A (en) | 2019-12-13 | 2019-12-13 | Gallocatechin and its application in preparation of intestinal pathogenic bacteria medicine and feed additive |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911279534.1A CN110946857A (en) | 2019-12-13 | 2019-12-13 | Gallocatechin and its application in preparation of intestinal pathogenic bacteria medicine and feed additive |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110946857A true CN110946857A (en) | 2020-04-03 |
Family
ID=69981378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911279534.1A Pending CN110946857A (en) | 2019-12-13 | 2019-12-13 | Gallocatechin and its application in preparation of intestinal pathogenic bacteria medicine and feed additive |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110946857A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114431340A (en) * | 2022-01-26 | 2022-05-06 | 广州微特加生物工程有限公司 | Application of catechin in preparation of animal feed additive and feed thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6068862A (en) * | 1993-06-30 | 2000-05-30 | Taiyo Kagaku Co., Ltd. | Tea-derived feed additive and animal feed containing the same |
-
2019
- 2019-12-13 CN CN201911279534.1A patent/CN110946857A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6068862A (en) * | 1993-06-30 | 2000-05-30 | Taiyo Kagaku Co., Ltd. | Tea-derived feed additive and animal feed containing the same |
Non-Patent Citations (2)
| Title |
|---|
| ELIZABETH A. MAZZIO等: "Natural product HTP screening for antibacterial (E.coli 0157:H7) and anti-inflammatory agents in (LPS from E. coli O111:B4) activated macrophages and microglial cells; focus on sepsis", 《BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE》 * |
| JU-DI FAN等: "Phenolic compounds from Acalypha australis", 《CHEMISTRY OF NATURAL COMPOUNDS》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114431340A (en) * | 2022-01-26 | 2022-05-06 | 广州微特加生物工程有限公司 | Application of catechin in preparation of animal feed additive and feed thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Megraud et al. | Activity of lansoprazole against Helicobacter pylori | |
| CN110123806B (en) | Application of epigallocatechin gallate in preparation of anti-streptococcus suis drugs | |
| KR20090009442A (en) | Antimicrobial and antiviral composition having improved sterilizing power | |
| Barrow et al. | Inhibition of colonization of the chicken caecum with Salmonella typhimurium by pre-treatment with strains of Escherichia coli | |
| CN110151752B (en) | Tea polyphenol composition and application thereof in preparation of anti-streptococcus suis medicines | |
| CN114129547B (en) | Application of carvacrol in improving sensitivity of methicillin-resistant staphylococcus aureus to beta-lactam antibiotics | |
| KR101819344B1 (en) | Bacillus safensis strain KACC 92124P and composition for comprising the same | |
| Oliveira et al. | Prevention of Salmonella infection by contact using intestinal flora of adult birds and/or a mixture of organic acids | |
| CN105001308B (en) | A kind of antibacterial peptide PD22 and application thereof | |
| CN110946857A (en) | Gallocatechin and its application in preparation of intestinal pathogenic bacteria medicine and feed additive | |
| CN108066758B (en) | Raccoon dog canine distemper-parvovirus enteritis bigeminal live vaccine and preparation method and application thereof | |
| KR20140031048A (en) | Composition and method for exterminating scutica and pathogenic bacteria in fishes | |
| KR20180131948A (en) | Pseudomonas extremorientalis strain KACC 81047BP and composition for comprising the same | |
| JP5483731B2 (en) | Production of storable raw egg suspension | |
| Stratev et al. | Antimicrobial resistance of β-haemolytic Aeromonas hydrophila strains isolated from rainbow trouts (Oncorhynchus mykiss). | |
| CN105012946A (en) | Pasteurellosis and duck colibacilosis combined propolis inactivated vaccine and preparation method thereof | |
| TWI729523B (en) | Bacillus amyloliquefaciens and use of the bacillus amyloliquefaciens for manufacturing compositions to inhibit or kill pathogenic bacteria and its metabolites for manufacturing compositions to inhibit or kill pathogenic bacteria | |
| CN114288286A (en) | Application of theaflavin in preparation of medicine for resisting avian pathogenic bacteria | |
| KR102077701B1 (en) | Vaccin composition containing novel inactivated Salmonella Gallinarum whole cells for preventing or treating Fowl Typhoid | |
| de Avila et al. | Effect of acidified drinking water on the recovery of Salmonella enteritidis from broiler crops | |
| CN111821322A (en) | Poultry micro-ecological oral preparation capable of replacing antibiotics and application thereof | |
| CN101926830A (en) | Antibacterial agent | |
| CN104740622A (en) | Pseudomonas aeruginosa, klebsiella and pasteurella triple-inactivated vaccine for mink | |
| KR102606461B1 (en) | Vaccine composition containing novel type of inactivated Salmonella Enteritidis whole cells for preventing or treating salmonellosis | |
| CN104250623A (en) | Mycoplasma hyorhinis strain, vaccine composition, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200403 |